Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL21P13 (ribosomal protein L21 pseudogene 13) is a human pseudogene related to the ribosomal protein L21 gene. Pseudogenes arise from gene duplication or retrotransposition but accumulate mutations that prevent their translation into a functional protein[1][2][3]. While the parental gene RPL21 encodes a structural component of the 60S ribosomal subunit involved in protein synthesis, RPL21P13 itself does not produce protein and is not implicated in biological processes, disease, or pharmacology. It is listed in gene databases primarily for genome annotation purposes and is not considered a canonical protein, receptor, or drug target[1][2][3].\n\nIf you require information about the functional ribosomal protein L21, which is an actual protein-coding gene and part of the 60S ribosomal subunit, refer to RPL21 rather than RPL21P13[5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 13 (RPL21P13).